The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Cancer Biosimilar Monoclonal Antibodies Market Research Report 2025

Global Cancer Biosimilar Monoclonal Antibodies Market Research Report 2025

Publishing Date : Apr, 2025

License Type :
 

Report Code : 2004859

No of Pages : 95

Ask Your Query
Synopsis
The global market for Cancer Biosimilar Monoclonal Antibodies was valued at US$ 6500 million in the year 2024 and is projected to reach a revised size of US$ 14340 million by 2031, growing at a CAGR of 12.0% during the forecast period.
Cancer biosimilar monoclonal antibodies refer to biological products developed through strict approval procedures after the expiration of the original monoclonal antibody drug patent, which are highly similar in quality, safety, and efficacy to the original drug. These generic products are not simple chemical generic drugs, but rather large molecule protein drugs produced through complex biotechnology processes, specifically targeting specific antigen targets in cancer treatment.
The global market for cancer biosimilar monoclonal antibodies has shown a rapid growth trend in recent years. Europe is currently the leading market for cancer biosimilar monoclonal antibodies, thanks to early policy support and a mature reimbursement system. Although the US market started relatively late, its growth rate has been astonishing in recent years. The active approval attitude of the FDA and the adjustment of medical insurance payment policies have driven market expansion. The Asian market, with China and India as its core growth engines, demonstrates explosive growth potential. The global market has formed a multi-level competitive structure. International giants such as Amgen, Samsung Bioepis, Sandoz, etc. dominate with their first mover advantage and global layout. At the same time, Chinese domestic enterprises such as Henlius, Innovent Biologics, and Qilu Pharmaceutical have not only gained an important position in the domestic market through continuous technological accumulation and clinical development, but also begun to export products to emerging markets and some developed countries. This pattern of "internal and external competition" is reshaping the global cancer biosimilar monoclonal antibody industry chain. In the coming years, the global cancer biosimilar monoclonal antibody market will face multiple turning points. As more original drug patents expire, the product pipeline will become more diverse. Meanwhile, the convergence of regulatory policies among countries will promote global market integration. In addition, the evolution of treatment models from single drug to combination therapy will also create new application scenarios and commercial opportunities for cancer biosimilar monoclonal antibodies.
This report aims to provide a comprehensive presentation of the global market for Cancer Biosimilar Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biosimilar Monoclonal Antibodies.
The Cancer Biosimilar Monoclonal Antibodies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Biosimilar Monoclonal Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Biosimilar Monoclonal Antibodies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Samsung Bioepis
Sandoz
Roche
Merck
Pfizer
Mylan
BristolMyers Squibb
Celltrion
Biocon
AbbVie
Teva Pharmaceutical Industries
Henlius
Innovent Biologics
Qilu Pharmaceutical
Sunshine Guojian
Bio-Thera Solutions
Biotech Pharma
Junshi Biosciences
Segment by Type
Mouse Derived Monoclonal Antibody
Human Mouse Chimeric Monoclonal Antibody
Human Derived Monoclonal Antibody
Fully Human Derived Monoclonal Antibody
Segment by Application
Solid Tumor Treatment
Hematological System Tumor Treatment
Combination Therapy
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biosimilar Monoclonal Antibodies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Mouse Derived Monoclonal Antibody
1.2.3 Human Mouse Chimeric Monoclonal Antibody
1.2.4 Human Derived Monoclonal Antibody
1.2.5 Fully Human Derived Monoclonal Antibody
1.3 Market by Application
1.3.1 Global Cancer Biosimilar Monoclonal Antibodies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumor Treatment
1.3.3 Hematological System Tumor Treatment
1.3.4 Combination Therapy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Perspective (2020-2031)
2.2 Global Cancer Biosimilar Monoclonal Antibodies Growth Trends by Region
2.2.1 Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Region (2020-2025)
2.2.3 Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Region (2026-2031)
2.3 Cancer Biosimilar Monoclonal Antibodies Market Dynamics
2.3.1 Cancer Biosimilar Monoclonal Antibodies Industry Trends
2.3.2 Cancer Biosimilar Monoclonal Antibodies Market Drivers
2.3.3 Cancer Biosimilar Monoclonal Antibodies Market Challenges
2.3.4 Cancer Biosimilar Monoclonal Antibodies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Biosimilar Monoclonal Antibodies Players by Revenue
3.1.1 Global Top Cancer Biosimilar Monoclonal Antibodies Players by Revenue (2020-2025)
3.1.2 Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Players (2020-2025)
3.2 Global Top Cancer Biosimilar Monoclonal Antibodies Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Cancer Biosimilar Monoclonal Antibodies Revenue
3.4 Global Cancer Biosimilar Monoclonal Antibodies Market Concentration Ratio
3.4.1 Global Cancer Biosimilar Monoclonal Antibodies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biosimilar Monoclonal Antibodies Revenue in 2024
3.5 Global Key Players of Cancer Biosimilar Monoclonal Antibodies Head office and Area Served
3.6 Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Product and Application
3.7 Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Biosimilar Monoclonal Antibodies Breakdown Data by Type
4.1 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Type (2020-2025)
4.2 Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Type (2026-2031)
5 Cancer Biosimilar Monoclonal Antibodies Breakdown Data by Application
5.1 Global Cancer Biosimilar Monoclonal Antibodies Historic Market Size by Application (2020-2025)
5.2 Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
6.2 North America Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025)
6.4 North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
7.2 Europe Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025)
7.4 Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
8.2 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2020-2025)
8.4 Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
9.2 Latin America Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025)
9.4 Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size (2020-2031)
10.2 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025)
10.4 Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Details
11.1.2 Amgen Business Overview
11.1.3 Amgen Cancer Biosimilar Monoclonal Antibodies Introduction
11.1.4 Amgen Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.1.5 Amgen Recent Development
11.2 Samsung Bioepis
11.2.1 Samsung Bioepis Company Details
11.2.2 Samsung Bioepis Business Overview
11.2.3 Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Introduction
11.2.4 Samsung Bioepis Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.2.5 Samsung Bioepis Recent Development
11.3 Sandoz
11.3.1 Sandoz Company Details
11.3.2 Sandoz Business Overview
11.3.3 Sandoz Cancer Biosimilar Monoclonal Antibodies Introduction
11.3.4 Sandoz Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.3.5 Sandoz Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Cancer Biosimilar Monoclonal Antibodies Introduction
11.4.4 Roche Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.4.5 Roche Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Cancer Biosimilar Monoclonal Antibodies Introduction
11.5.4 Merck Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.5.5 Merck Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Details
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Cancer Biosimilar Monoclonal Antibodies Introduction
11.6.4 Pfizer Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.6.5 Pfizer Recent Development
11.7 Mylan
11.7.1 Mylan Company Details
11.7.2 Mylan Business Overview
11.7.3 Mylan Cancer Biosimilar Monoclonal Antibodies Introduction
11.7.4 Mylan Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.7.5 Mylan Recent Development
11.8 BristolMyers Squibb
11.8.1 BristolMyers Squibb Company Details
11.8.2 BristolMyers Squibb Business Overview
11.8.3 BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Introduction
11.8.4 BristolMyers Squibb Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.8.5 BristolMyers Squibb Recent Development
11.9 Celltrion
11.9.1 Celltrion Company Details
11.9.2 Celltrion Business Overview
11.9.3 Celltrion Cancer Biosimilar Monoclonal Antibodies Introduction
11.9.4 Celltrion Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.9.5 Celltrion Recent Development
11.10 Biocon
11.10.1 Biocon Company Details
11.10.2 Biocon Business Overview
11.10.3 Biocon Cancer Biosimilar Monoclonal Antibodies Introduction
11.10.4 Biocon Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.10.5 Biocon Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Cancer Biosimilar Monoclonal Antibodies Introduction
11.11.4 AbbVie Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.11.5 AbbVie Recent Development
11.12 Teva Pharmaceutical Industries
11.12.1 Teva Pharmaceutical Industries Company Details
11.12.2 Teva Pharmaceutical Industries Business Overview
11.12.3 Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Introduction
11.12.4 Teva Pharmaceutical Industries Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.12.5 Teva Pharmaceutical Industries Recent Development
11.13 Henlius
11.13.1 Henlius Company Details
11.13.2 Henlius Business Overview
11.13.3 Henlius Cancer Biosimilar Monoclonal Antibodies Introduction
11.13.4 Henlius Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.13.5 Henlius Recent Development
11.14 Innovent Biologics
11.14.1 Innovent Biologics Company Details
11.14.2 Innovent Biologics Business Overview
11.14.3 Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Introduction
11.14.4 Innovent Biologics Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.14.5 Innovent Biologics Recent Development
11.15 Qilu Pharmaceutical
11.15.1 Qilu Pharmaceutical Company Details
11.15.2 Qilu Pharmaceutical Business Overview
11.15.3 Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Introduction
11.15.4 Qilu Pharmaceutical Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.15.5 Qilu Pharmaceutical Recent Development
11.16 Sunshine Guojian
11.16.1 Sunshine Guojian Company Details
11.16.2 Sunshine Guojian Business Overview
11.16.3 Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Introduction
11.16.4 Sunshine Guojian Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.16.5 Sunshine Guojian Recent Development
11.17 Bio-Thera Solutions
11.17.1 Bio-Thera Solutions Company Details
11.17.2 Bio-Thera Solutions Business Overview
11.17.3 Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Introduction
11.17.4 Bio-Thera Solutions Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.17.5 Bio-Thera Solutions Recent Development
11.18 Biotech Pharma
11.18.1 Biotech Pharma Company Details
11.18.2 Biotech Pharma Business Overview
11.18.3 Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Introduction
11.18.4 Biotech Pharma Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.18.5 Biotech Pharma Recent Development
11.19 Junshi Biosciences
11.19.1 Junshi Biosciences Company Details
11.19.2 Junshi Biosciences Business Overview
11.19.3 Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Introduction
11.19.4 Junshi Biosciences Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
11.19.5 Junshi Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
List of Tables
Table 1. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Mouse Derived Monoclonal Antibody
Table 3. Key Players of Human Mouse Chimeric Monoclonal Antibody
Table 4. Key Players of Human Derived Monoclonal Antibody
Table 5. Key Players of Fully Human Derived Monoclonal Antibody
Table 6. Global Cancer Biosimilar Monoclonal Antibodies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2020-2025)
Table 10. Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2026-2031)
Table 12. Cancer Biosimilar Monoclonal Antibodies Market Trends
Table 13. Cancer Biosimilar Monoclonal Antibodies Market Drivers
Table 14. Cancer Biosimilar Monoclonal Antibodies Market Challenges
Table 15. Cancer Biosimilar Monoclonal Antibodies Market Restraints
Table 16. Global Cancer Biosimilar Monoclonal Antibodies Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Players (2020-2025)
Table 18. Global Top Cancer Biosimilar Monoclonal Antibodies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biosimilar Monoclonal Antibodies as of 2024)
Table 19. Ranking of Global Top Cancer Biosimilar Monoclonal Antibodies Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Cancer Biosimilar Monoclonal Antibodies Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Headquarters and Area Served
Table 22. Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Product and Application
Table 23. Global Key Players of Cancer Biosimilar Monoclonal Antibodies, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2020-2025)
Table 27. Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2026-2031)
Table 29. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2020-2025)
Table 31. Global Cancer Biosimilar Monoclonal Antibodies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Cancer Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2026-2031)
Table 33. North America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size by Country (2026-2031) & (US$ Million)
Table 48. Amgen Company Details
Table 49. Amgen Business Overview
Table 50. Amgen Cancer Biosimilar Monoclonal Antibodies Product
Table 51. Amgen Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 52. Amgen Recent Development
Table 53. Samsung Bioepis Company Details
Table 54. Samsung Bioepis Business Overview
Table 55. Samsung Bioepis Cancer Biosimilar Monoclonal Antibodies Product
Table 56. Samsung Bioepis Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 57. Samsung Bioepis Recent Development
Table 58. Sandoz Company Details
Table 59. Sandoz Business Overview
Table 60. Sandoz Cancer Biosimilar Monoclonal Antibodies Product
Table 61. Sandoz Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 62. Sandoz Recent Development
Table 63. Roche Company Details
Table 64. Roche Business Overview
Table 65. Roche Cancer Biosimilar Monoclonal Antibodies Product
Table 66. Roche Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 67. Roche Recent Development
Table 68. Merck Company Details
Table 69. Merck Business Overview
Table 70. Merck Cancer Biosimilar Monoclonal Antibodies Product
Table 71. Merck Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 72. Merck Recent Development
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Cancer Biosimilar Monoclonal Antibodies Product
Table 76. Pfizer Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Mylan Company Details
Table 79. Mylan Business Overview
Table 80. Mylan Cancer Biosimilar Monoclonal Antibodies Product
Table 81. Mylan Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 82. Mylan Recent Development
Table 83. BristolMyers Squibb Company Details
Table 84. BristolMyers Squibb Business Overview
Table 85. BristolMyers Squibb Cancer Biosimilar Monoclonal Antibodies Product
Table 86. BristolMyers Squibb Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 87. BristolMyers Squibb Recent Development
Table 88. Celltrion Company Details
Table 89. Celltrion Business Overview
Table 90. Celltrion Cancer Biosimilar Monoclonal Antibodies Product
Table 91. Celltrion Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 92. Celltrion Recent Development
Table 93. Biocon Company Details
Table 94. Biocon Business Overview
Table 95. Biocon Cancer Biosimilar Monoclonal Antibodies Product
Table 96. Biocon Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 97. Biocon Recent Development
Table 98. AbbVie Company Details
Table 99. AbbVie Business Overview
Table 100. AbbVie Cancer Biosimilar Monoclonal Antibodies Product
Table 101. AbbVie Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 102. AbbVie Recent Development
Table 103. Teva Pharmaceutical Industries Company Details
Table 104. Teva Pharmaceutical Industries Business Overview
Table 105. Teva Pharmaceutical Industries Cancer Biosimilar Monoclonal Antibodies Product
Table 106. Teva Pharmaceutical Industries Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 107. Teva Pharmaceutical Industries Recent Development
Table 108. Henlius Company Details
Table 109. Henlius Business Overview
Table 110. Henlius Cancer Biosimilar Monoclonal Antibodies Product
Table 111. Henlius Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 112. Henlius Recent Development
Table 113. Innovent Biologics Company Details
Table 114. Innovent Biologics Business Overview
Table 115. Innovent Biologics Cancer Biosimilar Monoclonal Antibodies Product
Table 116. Innovent Biologics Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 117. Innovent Biologics Recent Development
Table 118. Qilu Pharmaceutical Company Details
Table 119. Qilu Pharmaceutical Business Overview
Table 120. Qilu Pharmaceutical Cancer Biosimilar Monoclonal Antibodies Product
Table 121. Qilu Pharmaceutical Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 122. Qilu Pharmaceutical Recent Development
Table 123. Sunshine Guojian Company Details
Table 124. Sunshine Guojian Business Overview
Table 125. Sunshine Guojian Cancer Biosimilar Monoclonal Antibodies Product
Table 126. Sunshine Guojian Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 127. Sunshine Guojian Recent Development
Table 128. Bio-Thera Solutions Company Details
Table 129. Bio-Thera Solutions Business Overview
Table 130. Bio-Thera Solutions Cancer Biosimilar Monoclonal Antibodies Product
Table 131. Bio-Thera Solutions Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 132. Bio-Thera Solutions Recent Development
Table 133. Biotech Pharma Company Details
Table 134. Biotech Pharma Business Overview
Table 135. Biotech Pharma Cancer Biosimilar Monoclonal Antibodies Product
Table 136. Biotech Pharma Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 137. Biotech Pharma Recent Development
Table 138. Junshi Biosciences Company Details
Table 139. Junshi Biosciences Business Overview
Table 140. Junshi Biosciences Cancer Biosimilar Monoclonal Antibodies Product
Table 141. Junshi Biosciences Revenue in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025) & (US$ Million)
Table 142. Junshi Biosciences Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
Table 146. Authors List of This Report


List of Figures
Figure 1. Cancer Biosimilar Monoclonal Antibodies Picture
Figure 2. Global Cancer Biosimilar Monoclonal Antibodies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Type: 2024 VS 2031
Figure 4. Mouse Derived Monoclonal Antibody Features
Figure 5. Human Mouse Chimeric Monoclonal Antibody Features
Figure 6. Human Derived Monoclonal Antibody Features
Figure 7. Fully Human Derived Monoclonal Antibody Features
Figure 8. Global Cancer Biosimilar Monoclonal Antibodies Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Application: 2024 VS 2031
Figure 10. Solid Tumor Treatment Case Studies
Figure 11. Hematological System Tumor Treatment Case Studies
Figure 12. Combination Therapy Case Studies
Figure 13. Cancer Biosimilar Monoclonal Antibodies Report Years Considered
Figure 14. Global Cancer Biosimilar Monoclonal Antibodies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Cancer Biosimilar Monoclonal Antibodies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Region: 2024 VS 2031
Figure 17. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Players in 2024
Figure 18. Global Cancer Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Cancer Biosimilar Monoclonal Antibodies Revenue in 2024
Figure 20. North America Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 22. United States Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 26. Germany Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Cancer Biosimilar Monoclonal Antibodies Market Share by Region (2020-2031)
Figure 34. China Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 42. Mexico Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Cancer Biosimilar Monoclonal Antibodies Market Share by Country (2020-2031)
Figure 46. Turkey Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Cancer Biosimilar Monoclonal Antibodies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Amgen Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 50. Samsung Bioepis Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 51. Sandoz Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 52. Roche Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 53. Merck Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 54. Pfizer Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 55. Mylan Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 56. BristolMyers Squibb Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 57. Celltrion Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 58. Biocon Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 59. AbbVie Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 60. Teva Pharmaceutical Industries Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 61. Henlius Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 62. Innovent Biologics Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 63. Qilu Pharmaceutical Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 64. Sunshine Guojian Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 65. Bio-Thera Solutions Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 66. Biotech Pharma Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 67. Junshi Biosciences Revenue Growth Rate in Cancer Biosimilar Monoclonal Antibodies Business (2020-2025)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock